Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS4 | Q9NRS4 | 11/20 | 0.62 |
| ▸ | STK39 | Q9UEW8 | 2/20 | 0.59 |
| ▸ | PARG | Q86W56 | 1/20 | 0.55 |
| ▸ | P2RX1 | P51575 | 5/20 | 0.53 |
| ▸ | P2RX4 | Q99571 | 3/20 | 0.53 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.53 |
| ▸ | PNLIP | P16233 | 5/20 | 0.51 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | IKBKB | O14920 | 1/20 | 0.50 |
| ▸ | CHUK | O15111 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 1/20 | 0.50 |
| ▸ | FLT3 | P36888 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MYLK | Q15746 | 1/20 | 0.50 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL330459 | 0.84 | TMPRSS4 (0.61) | TMPRSS4STK39PARGP2RX1P2RX4 | |
| SCHEMBL330265 | 0.80 | TMPRSS4 (0.75) | TMPRSS4STK39P2RX1P2RX4P2RX7 | |
| SCHEMBL13812719 | 0.78 | TMPRSS4 (0.85) | TMPRSS4P2RX1P2RX4P2RX7SLC2A1 | |
| SCHEMBL14885891 | 0.78 | TMPRSS4 (1.00) | TMPRSS4P2RX1P2RX4P2RX7SLC2A1 | |
| SCHEMBL24438027 | 0.77 | PNLIP (0.82) | STK39P2RX1PNLIPMEN1KMT2A | |
| SCHEMBL29655162 | 0.77 | PNLIP (0.82) | STK39P2RX1PNLIPMEN1KMT2A | |
| SCHEMBL330128 | 0.77 | TMPRSS4 (1.00) | TMPRSS4P2RX1P2RX4P2RX7SLC2A1 | |
| SCHEMBL330282 | 0.77 | TMPRSS4 (0.83) | TMPRSS4P2RX1P2RX4P2RX7SLC2A1 | |
| SCHEMBL330225 | 0.74 | TMPRSS4 (0.79) | TMPRSS4P2RX1P2RX4P2RX7SLC2A1 | |
| SCHEMBL14886085 | 0.74 | TMPRSS4 (1.00) | TMPRSS4P2RX1P2RX4P2RX7SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192122-A2 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-07-30 | — | — | US | claimed |
| US-20080249071-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2008-10-09 | — | — | US | claimed |
| EP-1847263-A2 | Inhibitors against the production and release of inflammatory cytokines | Institute of Medicinal Molecular Design, Inc. (JP) | 2007-10-24 | — | — | EP | claimed |
| US-7019016-B2 | Therapy of sensorineural hearing loss in a mammal by administering NR2B subunit selective N-methyl-D-aspartate (NMDA) NR2B subtype receptor antagonist | PFIZER INC (US) | 2006-03-28 | — | — | US | claimed |
| US-6958351-B2 | NMDA NR2B antagonists for treatment | PFIZER INC (US) | 2005-10-25 | — | — | US | claimed |
| US-20040259877-A1 | Inhibitors against the production and release of inflammatory cytokines | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2004-12-23 | — | — | US | claimed |
| US-20040192763-A1 | NMDA NR2B antagonists for treatment | PFIZER, INC. | 2004-09-30 | — | — | US | claimed |
| US-20040162312-A1 | NMDA NR2B antagonists for treatment | PFIZER PRODUCTS INC. | 2004-08-19 | — | — | US | claimed |
| EP-1352650-A1 | INHIBITORS AGAINST THE PRODUCTION AND RELEASE OF INFLAMMATORY CYTOKINES | Institute of Medicinal Molecular Design, Inc. (JP) | 2003-10-15 | — | — | EP | claimed |
| US-20010007872-A1 | METHOD OF TREATING ACUTE, CHRONIC AND/OR NEUROPATHIC PAIN | MENNITI FRANK S (US) | 2001-07-12 | — | — | US | claimed |
| US-8263657-B2 | Blocking neurokinins; using a benzene compound containing hydroxy or acetoxy group; antiinflammatory agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2012-09-11 | — | — | US | disclosed |
| US-8097759-B2 | Inflammatory cytokine release inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20100274051-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2010-10-28 | — | — | US | disclosed |
| US-20090192122-A2 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-07-30 | — | — | US | disclosed |
| US-20080318956-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2008-12-25 | — | — | US | disclosed |
| EP-1352650-A1 | INHIBITORS AGAINST THE PRODUCTION AND RELEASE OF INFLAMMATORY CYTOKINES | Institute of Medicinal Molecular Design, Inc. (JP) | 2003-10-15 | — | — | EP | disclosed |
| US-20020072538-A1 | NMDA NR2B antagonists for treatment | PFIZER INC. | 2002-06-13 | — | — | US | disclosed |
| EP-1199068-A2 | NMDA NR2B antagonists for treating depression and neurodegenerative disorders | Pfizer Products Inc. (US) | 2002-04-24 | — | — | EP | disclosed |
| EP-1199067-A2 | Prophylactic use of N-Methyl-D-Aspartate (NMDA) antagonists | Pfizer Products Inc. (US) | 2002-04-24 | — | — | EP | disclosed |
| EP-1186303-A2 | Pharmaceutical combinations, for the treatment of stroke and traumatic brain injury, containing a neutrophil inhibiting factor and an selective NMDA-NR2B receptor antagonist | Pfizer Products Inc. (US) | 2002-03-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010007872-A1 | METHOD OF TREATING ACUTE, CHRONIC AND/OR NEUROPATHIC PAIN | GRIN1, GRIN3A, GRIN3B | TMPRSS4 3687/4885STK39 4281/4885PARG 3675/4885 |
| US-20040192763-A1 | NMDA NR2B antagonists for treatment | GRIN2B, GRIN2A, GRIN1 | TMPRSS4 2212/4885STK39 3539/4885PARG 3482/4885 |
| US-20040162312-A1 | NMDA NR2B antagonists for treatment | GRIN2B, GRIN2A, GRIN1 | TMPRSS4 2212/4885STK39 3539/4885PARG 3482/4885 |
| US-20100274051-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | TMPRSS4 1813/4885STK39 3946/4885PARG 4285/4885 |
| US-20090192122-A2 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | TMPRSS4 1647/4885STK39 4023/4885PARG 4225/4885 |
| US-20080249071-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | TMPRSS4 1647/4885STK39 4023/4885PARG 4225/4885 |
| US-20080318956-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | TMPRSS4 1647/4885STK39 4023/4885PARG 4225/4885 |
| US-20020072538-A1 | NMDA NR2B antagonists for treatment | GRIN2B, GRIN2A, GRIN1 | TMPRSS4 2212/4885STK39 3539/4885PARG 3482/4885 |
| US-20040259877-A1 | Inhibitors against the production and release of inflammatory cytokines | NFKBIA, IL1B, IKBKB | TMPRSS4 3292/4885STK39 4673/4885PARG 4155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.